I just looked on the NICE website, they did a review of canaloplasty in 2022 and found no significant issues with safety and efficacy and recommend the procedure (amongst other MIGS). They did indicate they'd prefer more data, so it would be nice to see a new review that incorporates the large volume of addition data supporting efficacy since that review was done
POTENTIAL RE-RATE CATALYST EVENT: RESULTS, page-107
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.0¢ |
Change
0.005(2.22%) |
Mkt cap ! $52.68M | |||
| Open | High | Low | Value | Volume |
| 23.0¢ | 24.0¢ | 23.0¢ | $36.78K | 159.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 52300 | 22.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.0¢ | 53718 | 1 |
View Market Depth
| Last trade - 14.44pm 23/08/2024 (20 minute delay) ? |
| EYE (ASX) Chart |